ITM Launches Lumara Bio to Advance Radiopharmaceutical Oncology Pipeline
Garching/Munich, Germany and Princeton, New Jersey – July 27, 2026 ITM Isotope Technologies Munich SE (ITM) has launched Lumara...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Garching/Munich, Germany and Princeton, New Jersey – July 27, 2026 ITM Isotope Technologies Munich SE (ITM) has launched Lumara...
RALEIGH, N.C. | July 9, 2026 Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has announced that the...
